CoChat

Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA2LEN Study

Bousquet, Jean, Bachert, Claus, Canonica, Giorgio W., Mullol, Joaquim, Van Cauwenberge, Paul, Jensen, Carsten Bindslev, Fokkens, Wystke J., Ring, Johannes, Keith, Paul, Gopalan, Gokul, Lorber, Richard, Zuberbier, Torsten, the ACCEPT-2 Study Group · 2010 · International Archives of Allergy and Immunology
Cited by 58

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background: The ARIA (Allergic Rhinitis and its Impact on Asthma) guidelines proposed a classification for allergic rhinitis based on the duration of symptoms (intermittent or persistent) rather than on the time of allergen exposure (seasonal or perennial). There had been no placebo-controlled, randomized, clinical trial of desloratadine (DL) in patients with persistent allergic rhinitis to date. Objectives: To assess the efficacy and safety of DL in patients with persistent allergic rhinitis based on the ARIA classification. Methods: Patients 12 years of age and older with persistent allergic rhinitis were assessed over 85 days of treatment with DL 5 mg once daily (n = 360) or placebo (n = 356). The primary endpoint was the AM/PM reflective total 5-symptom score (T5SS) averaged over days 1–29. Secondary endpoints included AM/PM instantaneous T5SS and individual symptoms, therapeutic response, symptom severity assessed by a visual analogue scale and quality of life. Results: The mean reduction in AM/PM reflective T5SS was significantly greater with DL than placebo over days 1–29 (–3.76 vs. –2.87, p < 0.001) and on each individual day (p < 0.05). The mean AM instantaneous T5SS was significantly reduced with DL compared with placebo as early as day 2 (–1.90 vs. –1.46; p < 0.001). The therapeutic response and improvement in quality of life were significantly greater with DL than placebo (p < 0.001 for each). The frequency of treatment-related adverse events was low and similar between DL (10.0%) and placebo (8.4%). Conclusions: This study showed DL to be effective and safe in the treatment of persistent allergic rhinitis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1159/000316351

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 58

Metadata

Authors
Bousquet, J., Bachert, C., Canonica, G. W., Mullol, J., Van Cauwenberge, P., Jensen, C. B., Fokkens, W. J., Ring, J., Keith, P., Gopalan, G., Lorber, R., Zuberbier, T., & the ACCEPT-2 Study Group
Venue
International Archives of Allergy and Immunology
Publisher
S. Karger AG
Published
2010
Volume
153
Issue
4
Pages
395-402
ISSN
  • 1018-2438 (ISSN-L)
  • 1423-0097
OpenAlex
W2038055897
Cited by
58
References
6
FWCI
3.44
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA2LEN Study. https://app.cochat.ai/papers/10.1159/000316351
The paper
Bousquet, J., Bachert, C., Canonica, G. W., Mullol, J., Van Cauwenberge, P., Jensen, C. B., Fokkens, W. J., Ring, J., Keith, P., Gopalan, G., Lorber, R., Zuberbier, T., & the ACCEPT-2 Study Group. (2010). Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA2LEN Study. International Archives of Allergy and Immunology. https://doi.org/10.1159/000316351

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.